Table 4

Range of net costs and QALYs resulting from scenarios and one-way sensitivity analyses

QALY or cost per person

Item varied

Lower

Upper


Base case (per person):

not applicable

not applicable

QALY gain 0.013

Net cost -£317 (ie cost saving for enoxaparin)

Event free time gained

0.004 QALYs

0.014 QALYs

Quality of life associated with event

0.012 QALYs

na

Treatment duration

-£298

-£320

Length of stay

Difference in length of stay

£42 (ie £3,305/QALY)

-£158

Cost per length of stay

-£236

na

Revascularisations

Difference in coronary artery bypass grafting rates

-£140

-£495

Difference in angioplasty rates

-£242

-£368

Cost of coronary artery bypass grafting

-£309

-£323

Cost of angioplasty

-£311

-£360

Unfractionated heparin costs

Unfractionated heparin loading dose and saline flush

-£314

-£318

Unfractionated heparin drawn-up in saline

-£313

-£318

Pump-related

-£312

-£318

Monitoring (activate partial thromboplastin time tests)

-£308

-£318

Nursing time

-£314

-£318

Enoxaparin costs

-£314

-£326

Scenario 3: Treatment of cardiac events

(not mean length of stay)

Myocardial infarction rate and recurrence of angina

-£174

-£184

Cost to treat acute myocardial infarction

-£181

-£187

Cost to treat angina

-£181

-£189


Notes: See Table 2 for ranges used. As there was little difference between scenarios 1 and 2, we amalgamated the results. Negative net costs indicate cost saving if using enoxaparin. Net costs and QALY gains are not shown where unaffected by parameter changes. na means not avaliable.

Nicholson et al. BMC Cardiovascular Disorders 2001 1:2   doi:10.1186/1471-2261-1-2

Open Data